Form 4: Atara Biotherapeutics Executive Receives Stock Awards

Eric J. Hyllengren, EVP, CFO and COO of Atara Biotherapeutics, was granted 34,050 restricted stock units on January 27, 2025, according to a Form 4 filing with the SEC.

Summary

• Eric J. Hyllengren, the EVP, CFO, and COO of Atara Biotherapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on January 27, 2025, where Hyllengren acquired 34,050 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest in eight equal installments starting on the second Quarterly Vesting Date following January 27, 2025, and continuing every quarter thereafter, subject to continuous service.
• Quarterly Vesting Dates are defined as March 1, May 15, August 15, and November 15 of each year, adjusted to the next business day if the date falls on a weekend or holiday.
• Following the reported transaction, Hyllengren beneficially owns 57,442 shares of Atara Biotherapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing related to executive compensation. The grant of RSUs is generally a positive sign, indicating the company's investment in its leadership, but it doesn't necessarily reflect a significant change in the company's outlook.

Positives

• The grant of RSUs to a key executive like the CFO and COO can be seen as an incentive to align their interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The vesting schedule of the RSUs extends into the future, contingent on the executive's continued service with the company.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the holdings of company insiders. This filing indicates Atara Biotherapeutics' ongoing use of equity-based compensation to incentivize its leadership team.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotechnology industry to attract and retain top talent.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedule of these RSUs is typical, with vesting occurring over several years to incentivize long-term commitment.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive incentive for the executive team.
• Employees may see it as a sign of the company's commitment to its leadership.

Key Dates